Passage Bio Inc’s filing revealed that its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $0.24 million on Dec 27 ’24. In the deal valued at $0.65 per share,373,645 shares were bought. As a result of this transaction, Lynx1 Capital Management LP now holds 9,256,953 shares worth roughly $7.68 million.
Then, ORBIMED ADVISORS LLC sold 230,321 shares, generating $138,193 in total proceeds. Upon selling the shares at $0.60, the 10% Owner now owns 7,404,869 shares.
Before that, ORBIMED ADVISORS LLC sold 54,181 shares. Passage Bio Inc shares valued at $45,512 were divested by the 10% Owner at a price of $0.84 per share. As a result of the transaction, ORBIMED ADVISORS LLC now holds 7,643,285 shares, worth roughly $6.34 million.
A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. JP Morgan also remained covering PASG and has decreased its forecast on March 08, 2022 with a “Neutral” recommendation from previously “an Overweight” rating. Goldman revised its rating on January 19, 2022. It rated PASG as “a Neutral” which previously was an “a Buy”.
Price Performance Review of PASG
On Friday, Passage Bio Inc [NASDAQ:PASG] saw its stock fall -0.12% to $0.83. Over the last five days, the stock has gained 25.63%. Passage Bio Inc shares have risen nearly 46.18% since the year began. Nevertheless, the stocks have fallen -5.82% over the past one year. While a 52-week high of $1.79 was reached on 01/02/25, a 52-week low of $0.45 was recorded on 01/02/25. SMA at 50 days reached $0.6735, while 200 days put it at $0.9046.
Levels Of Support And Resistance For PASG Stock
The 24-hour chart illustrates a support level at 0.7743, which if violated will result in even more drops to 0.7195. On the upside, there is a resistance level at 0.8895. A further resistance level may holdings at 0.9499. The Relative Strength Index (RSI) on the 14-day chart is 58.85, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0574, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 40.87%. Stochastics %K at 48.16% indicates the stock is a holding.
How much short interest is there in Passage Bio Inc?
A steep rise in short interest was recorded in Passage Bio Inc stocks on 2024-10-31, dropping by 59917.0 shares to a total of 1.64 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 1.7 million shares. There was a decline of -3.65%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on July 01, 2021 when Raymond James began covering the stock and recommended ‘”an Outperform”‘ rating along with a $29 price target.
